Interleukine-6 and high-sensitive CRP plasma levels and antidepressant response- A secondary analysis from the Early Medication Change (EMC) trial

Introduction Although the available pharmacological treatments of major depressive disorder (MDD) are well established, there is a great variability in patient´s individual response. Therefore, reliable predictors to guide treatment decisions are needed. Growing evidence in literature suggests alterations in IL-6 and hs-CRP levels in depression, but findings on antidepressant treatment response prediction are fare to be conclusive. Thus, our aim was to investigate the course of both parameters between later responders and non-responders to antidepressant treatment.